New hope for myeloma patients: testing a potential alternative treatment

NCT ID NCT07477587

Summary

This study aims to test a new, under-the-skin injection called HLX15-SC for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. Researchers will compare it to an existing approved treatment (DARZALEX FASPRO®) to see if it works similarly in the body and is safe. The goal is to see if this new option can help control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • American Oncology Network Vista Oncology Division / Physician partner associate

    Olympia, Washington, 98506, United States

  • Cancer Specialists of North Florida

    Jacksonville, Florida, 32256, United States

  • D&H National Research Center

    Margate, Florida, 33063, United States

  • Florida Clinical Trials Group

    Plantation, Florida, 33322, United States

  • Florida Clinical Trials Group

    Tamarac, Florida, 33321, United States

  • Highlands Oncology Group, PA

    Springdale, Arkansas, 72762, United States

  • Oncology Consultants (P1 Trials -Exigent Network)

    Houston, Texas, 77030, United States

  • Pontchartrain Cancer Center

    Covington, Louisiana, 70433, United States

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, 200032, China

Conditions

Explore the condition pages connected to this study.